Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Jerome Ritz, MD


Medical Oncology

No Ratings Available - Why Not? Make an Appointment

Physician

  • Executive Director, Connell and O'Reilly Families Cell Manipulation Core Facility
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Stem cell/bone marrow transplant
  • Tumor immunology

Contact Information

  • Office Phone Number617-632-3465
  • Fax617-632-5167

Bio

Dr. Ritz received his MD from Chicago Medical School in 1972, followed by residency in internal medicine at the University of Wisconsin Hospital and Clinics, Madison. He completed a clinical fellowship in hematology and oncology at Beth Israel Hospital, and a research fellowship at DFCI, where he joined the staff in 1980. Since 1996, he has been director of the Connell and O'Reilly Families Cell Manipulation Core.

Board Certification:

  • Hematology, 1980
  • Internal Medicine, 1975

Fellowship:

  • Beth Israel Deaconess Medical Center, Hematology & Oncology
  • Dana-Farber Cancer Institute, Tumor Immunology

Residency:

  • University of Wisconsin Hospitals, Internal Medicine

Medical School:

  • Chicago Medical School

Recent Awards:

  • Stohlman Scholar Award, Leukemia Society of America 1988
  • Elected Member, American Society for Clinical Investigation 1990

Research

Hematopoietic Stem Cell Transplantation, Graft versus Host Disease, Graft versus Leukemia, Cellular Therapy and Immunotherapy

Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for patients with hematologic malignancies, but continues to be associated with severe toxicities. Both the efficacy and toxicity of HSCT are mediated by donor immune cells. Immune responses that target antigens expressed on recipient leukemia cells (termed graft versus leukemia – GVL) play an important role in eradicating residual tumor cells and preventing leukemia relapse after transplant. In contrast, immune responses that target antigens expressed by normal tissues in the recipient are the primary mediators of graft versus host disease (GVHD) and thus lead to substantial toxicities. 

Although donor T cells are the primary immune cells responsible for GVL and GVHD, studies from our laboratory demonstrated that donor B cells also play a role in these responses. To examine the role of B cells we determined whether patients developed antibodies specific for minor histocompatibility antigens such as Y-chromosome encoded proteins (H-Y antigens) after HSCT. While males are tolerant to these self-proteins, female T cells develop strong responses to these antigens after transplantation into male recipients. Our studies demonstrated that antibodies specific for H-Y antigens developed in approximately 50% of male recipients with female donors but not in male patients with male donors. Importantly, the incidence of chronic GVHD was significantly higher and the risk of relapse was significantly lower in patients with H-Y antibodies. These studies provided evidence that B cell responses contribute to GVHD as well as GVL and also suggested that targeting donor B cells might offer a new therapeutic approach for chronic GVHD. This was confirmed by clinical trials demonstrating the efficacy of rituximab in patients with persistent chronic GVHD.  Further studies evaluating the efficacy of rituximab for prevention of chronic GVHD are also underway. Current studies in my laboratory focus on defining the mechanisms whereby donor B cells and antibodies specific for recipient antigens contribute to GVL and GVHD.

Regulatory T cells (Treg) are known to play a critical role in immune tolerance and deficiencies of Treg contribute to the development of autoimmune diseases. Studies from our laboratory demonstrated that patients with chronic GVHD were deficient in Treg and inadequate reconstitution of Treg after transplant helps explain the inability of some patients to become immunologically tolerant to their own tissues. These findings also suggested that enhancement of Treg might restore immune tolerance and control GVHD. This was recently confirmed in clinical trials showing that administration of low doses of IL-2, a critical cytokine required for maintenance of Treg, resulted in the selective expansion of Treg and significant clinical improvement in approximately 50% of patients with active chronic GVHD. Current studies in my laboratory focus on the identification of critical factors that regulate homeostasis of Treg in normal individuals and in patients after HSCT. These studies also examine the effects of exogenous IL-2 on Treg homeostasis and characterization of the mechanisms whereby IL-2 enhances Treg numbers and function in patients with GVHD.

In addition to the specific projects described above, my laboratory is also interested in developing other novel immune therapies for hematologic malignancies. These would include cytokines, immune modulating antibodies or other agents, cancer vaccines and adoptive cellular therapies. Our laboratory has the ability to develop novel therapies of many types and to evaluate the immunologic effects of these new approaches in patients enrolled on the clinical trials conducted to evaluate these methods. 

Impact of Cryopreservation and Transit Times of Allogeneic Grafts on Hematopoietic and Immune Reconstitution. Blood Adv. 2021 Sep 28.
View in: PubMed

Author Correction: Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nat Immunol. 2021 Sep 14.
View in: PubMed

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 Aug 26.
View in: PubMed

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 Jun 10; 137(23):3212-3217.
View in: PubMed

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J Transl Autoimmun. 2021; 4:100103.
View in: PubMed

Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nat Immunol. 2021 04; 22(4):520-529.
View in: PubMed

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplant Cell Ther. 2021 06; 27(6):452-466.
View in: PubMed

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Front Immunol. 2020; 11:608485.
View in: PubMed

Comparative analysis of cell therapy infusion workflows at clinical sites. Cytotherapy. 2021 04; 23(4):285-292.
View in: PubMed

Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364.
View in: PubMed

Maturation and Phenotypic Heterogeneity of Human CD4+ Regulatory T Cells From Birth to Adulthood and After Allogeneic Stem Cell Transplantation. Front Immunol. 2020; 11:570550.
View in: PubMed

Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med (N Y). 2021 Apr 09; 2(4):411-422.e5.
View in: PubMed

Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature. 2021 02; 590(7844):157-162.
View in: PubMed

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Front Immunol. 2020; 11:580328.
View in: PubMed

Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021 01 21; 384(3):205-215.
View in: PubMed

Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561).
View in: PubMed

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
View in: PubMed

Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020 09 01; 130(9):4624-4636.
View in: PubMed

Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury and Predicts COVID-19 Severity. medRxiv. 2020 Jul 29.
View in: PubMed

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 09 20; 38(27):3095-3106.
View in: PubMed

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
View in: PubMed

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191.
View in: PubMed

T Cell Clonal Dynamics Determined by High-Resolution TCR-ß Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 09; 26(9):1567-1574.
View in: PubMed

Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. N Engl J Med. 2020 05 14; 382(20):1926-1932.
View in: PubMed

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 05 12; 4(9):1881-1893.
View in: PubMed

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126.
View in: PubMed

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40.
View in: PubMed

A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
View in: PubMed

Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. Bone Marrow Transplant. 2020 09; 55(9):1821-1823.
View in: PubMed

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561.
View in: PubMed

Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Hematol Int. 2019 Dec; 1(4):201-204.
View in: PubMed

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; 3(14):2199-2204.
View in: PubMed

Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Biol Blood Marrow Transplant. 2019 11; 25(11):2143-2151.
View in: PubMed

Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clin Immunol. 2019 10; 207:18-23.
View in: PubMed

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979.
View in: PubMed

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):984-994.
View in: PubMed

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29.
View in: PubMed

Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830.
View in: PubMed

Clinical Metabolomics Identifies Blood Serum Branched Chain Amino Acids as Potential Predictive Biomarkers for Chronic Graft vs. Host Disease. Front Oncol. 2019; 9:141.
View in: PubMed

Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease. Front Immunol. 2019; 10:334.
View in: PubMed

A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica. 2019 07; 104(7):e314-e317.
View in: PubMed

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
View in: PubMed

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112.
View in: PubMed

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99.
View in: PubMed

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant. 2018 11; 24(11):2216-2223.
View in: PubMed

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Cytotherapy. 2018 07; 20(7):952-963.
View in: PubMed

NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. Blood Adv. 2018 06 26; 2(12):1412-1416.
View in: PubMed

Biomanufacturing for clinically advanced cell therapies. Nat Biomed Eng. 2018 06; 2(6):362-376.
View in: PubMed

Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2344-2353.
View in: PubMed

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740.
View in: PubMed

Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402.
View in: PubMed

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018 03; 103(3):522-530.
View in: PubMed

Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol. 2018 Apr; 137(2):269-278.
View in: PubMed

Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses. Proc Natl Acad Sci U S A. 2018 01 23; 115(4):E686-E695.
View in: PubMed

Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017 Nov 14; 1(24):2269-2279.
View in: PubMed

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 2017 12 28; 130(26):2889-2899.
View in: PubMed

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 02; 8(2):216-233.
View in: PubMed

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017 Dec 20; 35(36):4003-4011.
View in: PubMed

An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
View in: PubMed

An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017 Jun 15; 2(12).
View in: PubMed

Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. Blood. 2017 06 15; 129(24):3256-3261.
View in: PubMed

Research Techniques Made Simple: Mass Cytometry Analysis Tools for Decrypting the Complexity of Biological Systems. J Invest Dermatol. 2017 05; 137(5):e43-e51.
View in: PubMed

Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017 07 06; 130(1):91-94.
View in: PubMed

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer Discov. 2017 08; 7(8):852-867.
View in: PubMed

Research Techniques Made Simple: Experimental Methodology for Single-Cell Mass Cytometry. J Invest Dermatol. 2017 04; 137(4):e31-e38.
View in: PubMed

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-ß production. Blood. 2017 05 04; 129(18):2570-2580.
View in: PubMed

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017 Jul 15; 123(14):2642-2650.
View in: PubMed

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clin Cancer Res. 2017 Jul 15; 23(14):3510-3519.
View in: PubMed

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017 04 13; 129(15):2186-2197.
View in: PubMed

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 03 09; 129(10):1380-1388.
View in: PubMed

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
View in: PubMed

Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
View in: PubMed

Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood. 2017 01 05; 129(1):22-29.
View in: PubMed

Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278.
View in: PubMed

Risk factors for reoperation after ileostomy reversal - Results from a prospective cohort study. Int J Surg. 2016 Dec; 36(Pt A):233-239.
View in: PubMed

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. Biol Blood Marrow Transplant. 2017 01; 23(1):103-112.
View in: PubMed

Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016 Dec; 175(5):841-850.
View in: PubMed

The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Feb; 23(2):211-234.
View in: PubMed

CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. Immunity. 2016 07 19; 45(1):209-23.
View in: PubMed

Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 08 18; 128(7):1013-7.
View in: PubMed

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016 10; 101(10):1251-1259.
View in: PubMed

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
View in: PubMed

Necessity of subcutaneous suction drains in ileostomy reversal (DRASTAR)-a randomized, controlled bi-centered trial. Langenbecks Arch Surg. 2016 Jun; 401(4):409-18.
View in: PubMed

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 04 28; 127(17):2144-54.
View in: PubMed

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016 05 19; 127(20):2489-97.
View in: PubMed

Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. Cancer Immunol Immunother. 2016 Mar; 65(3):355-66.
View in: PubMed

Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016 Apr; 101(4):499-505.
View in: PubMed

Dramatic Expansion of HSCs: New Possibilities for HSC Transplants? Cell Stem Cell. 2016 Jan 07; 18(1):10-2.
View in: PubMed

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57.
View in: PubMed

Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. Haematologica. 2016 Jan; 101(1):e30-3.
View in: PubMed

IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. PLoS One. 2015; 10(7):e0132564.
View in: PubMed

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1907-13.
View in: PubMed

Reconstitution of T Cell Immunity after Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1151-2.
View in: PubMed

Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94.
View in: PubMed

Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86.
View in: PubMed

Interferon-?-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015 Jun; 4(6):e1008824.
View in: PubMed

Aberrant B-cell homeostasis in chronic GVHD. Blood. 2015 Mar 12; 125(11):1703-7.
View in: PubMed

Reprint of: B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Feb; 21(2 Suppl):S11-8.
View in: PubMed

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2015 May; 21(5):873-80.
View in: PubMed

Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. Clin Cancer Res. 2015 Mar 01; 21(5):1010-8.
View in: PubMed

B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jan; 21(1):16-23.
View in: PubMed

A modified ?-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014 Oct 09; 371(15):1407-17.
View in: PubMed

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov; 124(11):4867-76.
View in: PubMed

Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6.
View in: PubMed

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
View in: PubMed

A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1737-43.
View in: PubMed

Current issues in chronic graft-versus-host disease. Blood. 2014 Jul 17; 124(3):374-84.
View in: PubMed

Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1516-21.
View in: PubMed

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17; 124(3):453-62.
View in: PubMed

Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508.
View in: PubMed

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
View in: PubMed

White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol. 2014 Jun; 89(6):591-7.
View in: PubMed

Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014 Apr; 89(4):404-9.
View in: PubMed

Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target. Exp Hematol. 2014 Apr; 42(4):307-316.e8.
View in: PubMed

Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75.
View in: PubMed

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb 27; 123(9):1412-21.
View in: PubMed

Tregs, HSCT, and acute GVHD: up close and personal. Blood. 2013 Sep 05; 122(10):1690-1.
View in: PubMed

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013 Oct 24; 122(17):3074-81.
View in: PubMed

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013 Aug 08; 369(6):529-39.
View in: PubMed

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
View in: PubMed

[What is the actual benefit of sigmoid resection for acute diverticulitis? : Functional outcome after surgical and conservative treatment]. Chirurg. 2013 Aug; 84(8):673-80.
View in: PubMed

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013 Aug 22; 122(8):1510-7.
View in: PubMed

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70.
View in: PubMed

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 03; 5(179):179ra43.
View in: PubMed

Identification of cytolytic CD161- CD56+ regulatory CD8 T cells in human peripheral blood. PLoS One. 2013; 8(3):e59545.
View in: PubMed

Probing circulating tumor cells in microfluidics. Lab Chip. 2013 Feb 21; 13(4):602-9.
View in: PubMed

Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 May; 19(5):804-11.
View in: PubMed

Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Respir Med. 2013 Feb; 107(2):276-83.
View in: PubMed

Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103.
View in: PubMed

B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood. 2012 Sep 20; 120(12):2529-36.
View in: PubMed

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3202-8.
View in: PubMed

A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26; 120(4):905-13.
View in: PubMed

Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest. 2012 Jul; 122(7):2369-83.
View in: PubMed

Expression of CD30 in patients with acute graft-versus-host disease. Blood. 2012 Jul 19; 120(3):691-6.
View in: PubMed

Development and implementation of a computerized system for collection, processing, and administration of cellular therapy products. J Oncol Pract. 2012 Sep; 8(5):262-6.
View in: PubMed

Reduction of wound infections in laparoscopic-assisted colorectal resections by plastic wound ring drapes (REDWIL)?--A randomized controlled trial. Langenbecks Arch Surg. 2012 Oct; 397(7):1079-85.
View in: PubMed

Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
View in: PubMed

Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66.
View in: PubMed

A clonal model for human CD8+ regulatory T cells: unrestricted contact-dependent killing of activated CD4+ T cells. Eur J Immunol. 2012 Jan; 42(1):69-79.
View in: PubMed

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012 Feb 09; 119(6):1570-80.
View in: PubMed

Time to put the CAR-T before the horse. Blood. 2011 Nov 03; 118(18):4761-2.
View in: PubMed

Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012 May; 18(5):805-12.
View in: PubMed

Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011 Dec 15; 118(25):6691-7.
View in: PubMed

Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011 Nov 03; 118(18):5021-30.
View in: PubMed

Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74.
View in: PubMed

Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation. 2011 Aug 15; 92(3):359-65.
View in: PubMed

[Acute sigmoid diverticulitis. Are operations more frequent since the introduction of laparoscopy and CT scanning?]. Chirurg. 2011 Aug; 82(8):701-6.
View in: PubMed

Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011 Apr; 121(4):1574-84.
View in: PubMed

MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One. 2011 Mar 08; 6(3):e16956.
View in: PubMed

Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood. 2011 Apr 21; 117(16):4315-22.
View in: PubMed

The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol. 2011 02; 12(2):126-31.
View in: PubMed

Preclinical regulatory validation of an engineered diaphragmatic tendon made with amniotic mesenchymal stem cells. J Pediatr Surg. 2011 Jan; 46(1):57-61.
View in: PubMed

Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. Transfusion. 2011 Jan; 51(1):137-47.
View in: PubMed

Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1196-204.
View in: PubMed

Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol. 2010 Dec; 85(12):967-71.
View in: PubMed

Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011 Feb 17; 117(7):2275-83.
View in: PubMed

B-cell-directed therapy for chronic graft-versus-host disease. Haematologica. 2010 Nov; 95(11):1811-3.
View in: PubMed

Predictors of permanent ileostomy after restorative proctocolectomy. Br J Surg. 2010 Oct; 97(10):1561-6.
View in: PubMed

Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010 May 15; 16(10):2729-39.
View in: PubMed

Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010 May; 120(5):1479-93.
View in: PubMed

Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5.
View in: PubMed

Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010 Mar 01; 16(5):1642-51.
View in: PubMed

NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant. 2010 May; 16(5):565-86.
View in: PubMed

Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 Feb 15; 70(4):1344-55.
View in: PubMed

Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
View in: PubMed

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010 Feb 01; 70(3):906-15.
View in: PubMed

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010 Jun; 16(6):792-800.
View in: PubMed

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in: PubMed

Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009 Dec; 41(12):1341-4.
View in: PubMed

Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S146-51.
View in: PubMed

Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. J Allergy Clin Immunol. 2009 Nov; 124(5):1062-9.e1-4.
View in: PubMed

[Laparoscopic appendectomy: is it worth the cost?]. Chirurg. 2009 Oct; 80(10):966-8.
View in: PubMed

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009 Oct 29; 114(18):3956-9.
View in: PubMed

Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):15825-30.
View in: PubMed

Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1066-76.
View in: PubMed

Revealing tumor immunity after hematopoietic stem cell transplantation. Clin Cancer Res. 2009 Jul 15; 15(14):4515-7.
View in: PubMed

Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Mar; 15(3):382-8.
View in: PubMed

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009 Apr 16; 113(16):3865-74.
View in: PubMed

Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. J Allergy Clin Immunol. 2008 Dec; 122(6):1185-93.
View in: PubMed

Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8.
View in: PubMed

Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008 Oct; 83(10):771-7.
View in: PubMed

Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation. Clin Cancer Res. 2008 Aug 15; 14(16):4997-9.
View in: PubMed

Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep; 36(9):1205-15.
View in: PubMed

Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol. J Pediatr Surg. 2008 Jun; 43(6):1164-9.
View in: PubMed

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1285-90.
View in: PubMed

A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):28-35.
View in: PubMed

Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol. 2007 Nov; 139(3):504-7.
View in: PubMed

High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007 Oct 15; 13(20):6107-14.
View in: PubMed

Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. Haematologica. 2007 May; 92(5):619-26.
View in: PubMed

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64.
View in: PubMed

Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood. 2007 Mar 01; 109(5):2001-7.
View in: PubMed

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64.
View in: PubMed

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55.
View in: PubMed

Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood. 2007 Feb 15; 109(4):1355-62.
View in: PubMed

Studying human regulatory T cells in vivo. Clin Cancer Res. 2006 Sep 15; 12(18):5265-7.
View in: PubMed

SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood. 2006 Oct 15; 108(8):2726-35.
View in: PubMed

IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006 Sep 01; 108(5):1571-9.
View in: PubMed

Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15; 108(2):756-62.
View in: PubMed

CD34+CD38- and CD34+HLA-DR- cells in bone marrow stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologus transplantation. Cytotherapy. 2006; 8:399-407.

Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol. 2006; 90:133-73.
View in: PubMed

Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res. 2005 Oct 15; 11(20):7209-19.
View in: PubMed

ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. Blood. 2006 Jan 01; 107(1):197-204.
View in: PubMed

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15; 106(13):4389-96.
View in: PubMed

Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood. 2005 Nov 15; 106(10):3639-45.
View in: PubMed

FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. Br J Haematol. 2005 Jul; 130(1):43-50.
View in: PubMed

Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15; 106(8):2903-11.
View in: PubMed

Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res. 2005 Jun 15; 11(12):4504-11.
View in: PubMed

Genomic analysis in lymphoid leukemias. Rev Clin Exp Hematol. 2005 Jun 01; 9(1):E3.
View in: PubMed

Bayesian error-in-variable survival model for the analysis of GeneChip arrays. Biometrics. 2005 Jun; 61(2):488-97.
View in: PubMed

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50.
View in: PubMed

Immune reconstitution after allogeneic stem cell transplantation. Haematologica. 2005 Jan; 90(1):5.
View in: PubMed

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8.
View in: PubMed

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4.
View in: PubMed

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; 10(15):5065-71.
View in: PubMed

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 15; 104(4):1224-6.
View in: PubMed

Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004 Apr 19; 199(8):1133-42.
View in: PubMed

Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004 Feb; 44(2):253-61.
View in: PubMed

A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J Immunol. 2004 Jan 01; 172(1):651-60.
View in: PubMed

Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer? Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):1-3.
View in: PubMed

Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood. 2004 Apr 01; 103(7):2771-8.
View in: PubMed

Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2003 Dec; 32(12):1145-51.
View in: PubMed

Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63.
View in: PubMed

Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol. 2003 Oct; 31(10):924-33.
View in: PubMed

Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004 Jan 01; 103(1):353-9.
View in: PubMed

Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 2003 May 15; 63(10):2561-8.
View in: PubMed

Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion. 2003 May; 43(5):614-21.
View in: PubMed

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9.
View in: PubMed

CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 2002 Oct 01; 62(19):5517-5522.
View in: PubMed

Allogeneic stem cell transplantation for multiple myeloma. Rev Clin Exp Hematol. 2002 Sep; 6(3):205-24.
View in: PubMed

A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003 Jan 01; 101(1):363-9.
View in: PubMed

Adult hematopoietic stem cell plasticity. Transfusion. 2002 Aug; 42(8):1096-101.
View in: PubMed

Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res. 2002 Jul; 8(7):2052-60.
View in: PubMed

Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors. Blood. 2002 Jun 15; 99(12):4634-7.
View in: PubMed

Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7.
View in: PubMed

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002 Jun; 117(4):828-34.
View in: PubMed

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24.
View in: PubMed

Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest Dermatol. 2002 Feb; 118(2):366-71.
View in: PubMed

Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(3):139-44.
View in: PubMed

Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32.
View in: PubMed

T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001 Aug 15; 98(4):934-9.
View in: PubMed

Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001 Aug 15; 98(4):1116-21.
View in: PubMed

CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7492-7.
View in: PubMed

Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation. Blood. 2001 Jun 15; 97(12):3860-6.
View in: PubMed

A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001 Apr 27; 71(8):1131-7.
View in: PubMed

CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9.
View in: PubMed

CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells. Exp Hematol. 2001 Feb; 29(2):209-20.
View in: PubMed

MR-guided interstitial laser-induced thermotherapy of hepatic metastasis combined with arterial blood flow reduction: technique and first clinical results in an open MR system. J Magn Reson Imaging. 2001 Jan; 13(1):31-6.
View in: PubMed

Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000 Sep; 106(5):705-14.
View in: PubMed

Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood. 2000 May 15; 95(10):3183-90.
View in: PubMed

Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant. 2000 Mar; 25(6):623-32.
View in: PubMed

[Laser-induced thermotherapy (LITT) for liver metastasis in an open 0.2T MRI]. Rofo. 2000 Feb; 172(2):175-8.
View in: PubMed

Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9.
View in: PubMed

Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant. 2000; 6(4):375-86.
View in: PubMed

Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999 Nov 15; 94(10):3325-33.
View in: PubMed

Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35.
View in: PubMed

CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology. 1999 May; 97(1):159-65.
View in: PubMed

The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol. 1999 Apr 15; 162(8):4472-81.
View in: PubMed

Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999 Apr; 5(4):444-7.
View in: PubMed

PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet. 1999 Feb; 8(2):185-93.
View in: PubMed

Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999 Feb; 17(2):561-8.
View in: PubMed

IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J Immunol. 1999 Jan 01; 162(1):299-304.
View in: PubMed

Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res. 1999 Jan; 5(1):9-16.
View in: PubMed

Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999; 5(4):262-8.
View in: PubMed

Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood. 1998 Oct 15; 92(8):2725-9.
View in: PubMed

Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc Natl Acad Sci U S A. 1998 Sep 15; 95(19):11348-53.
View in: PubMed

Dysregulation of interleukin-2 receptor beta and interleukin-2 receptor gamma expression during HIV infection. Eur Cytokine Netw. 1998 Sep; 9(3 Suppl):97-101.
View in: PubMed

Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. J Clin Invest. 1998 Aug 01; 102(3):561-75.
View in: PubMed

TAL1 expression does not occur in the majority of T-ALL blasts. Br J Haematol. 1998 Jul; 102(2):449-57.
View in: PubMed

CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998 Jun; 21(12):1177-81.
View in: PubMed

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998 May 15; 91(10):3671-80.
View in: PubMed

IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene. 1998 May 14; 16(19):2503-12.
View in: PubMed

Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1. Blood. 1998 Feb 15; 91(4):1341-54.
View in: PubMed

Participation of the CD94 receptor complex in costimulation of human natural killer cells. J Immunol. 1998 Feb 15; 160(4):1618-26.
View in: PubMed

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998 Jan; 16(1):13-8.
View in: PubMed

Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis. 1998; 13(4):164-8.
View in: PubMed

Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. Blood. 1998 Jan 01; 91(1):165-72.
View in: PubMed

Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood. 1997 Dec 15; 90(12):4996-5001.
View in: PubMed

B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997 Dec 15; 100(12):3140-8.
View in: PubMed

Altered tyrosine phosphorylation via the very late antigen (VLA)/beta1 integrin stimulation is associated with impaired T-cell signaling through VLA-4 after allogeneic bone marrow transplantation. Blood. 1997 Nov 15; 90(10):4222-9.
View in: PubMed

In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Nov; 3(5):267-72.
View in: PubMed

Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood. 1997 Oct 15; 90(8):2962-8.
View in: PubMed

Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol. 1997 Sep 15; 159(6):3057-67.
View in: PubMed

CD94 ligation induces apoptosis in a subset of IL-2-stimulated NK cells. J Immunol. 1997 Sep 01; 159(5):2154-60.
View in: PubMed

Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest. 1997 Aug 15; 100(4):855-66.
View in: PubMed

Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol. 1997 May; 97(2):409-17.
View in: PubMed

CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997 Apr 15; 89(8):3039-47.
View in: PubMed

CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant. 1997 Apr; 3(1):11-7.
View in: PubMed

Expression of the IL-2 receptor gamma subunit in resting human CD4 T lymphocytes: mRNA is constitutively transcribed and the protein stored as an intracellular component. Int Immunol. 1997 Apr; 9(4):573-80.
View in: PubMed

Interferon-gamma and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. Eur J Immunol. 1997 Mar; 27(3):647-52.
View in: PubMed

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997 Mar; 3(3):409-17.
View in: PubMed

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol. 1997 Feb; 15(2):723-34.
View in: PubMed

Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. Clin Cancer Res. 1997 Jan; 3(1):17-24.
View in: PubMed

TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996 Dec 01; 88(11):4252-8.
View in: PubMed

Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation. 1996 Nov 15; 62(9):1358-60.
View in: PubMed

CD2-CD58 interaction and the control of T-cell interleukin-12 responsiveness. Adhesion molecules link innate and acquired immunity. Ann N Y Acad Sci. 1996 Oct 31; 795:71-81.
View in: PubMed

High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 01; 88(7):2780-6.
View in: PubMed

Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2228-35.
View in: PubMed

Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2334-41.
View in: PubMed

Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. J Immunol. 1996 Sep 01; 157(5):1886-93.
View in: PubMed

R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Eur J Immunol. 1996 Sep; 26(9):2149-54.
View in: PubMed

Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. Transfusion. 1996 Sep; 36(9):782-8.
View in: PubMed

Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. Blood. 1996 Mar 15; 87(6):2419-27.
View in: PubMed

Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin Cancer Res. 1996 Mar; 2(3):493-9.
View in: PubMed

Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol. 1996 Mar; 148(3):847-53.
View in: PubMed

Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. Immunology. 1996 Mar; 87(3):402-7.
View in: PubMed

Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996 Feb; 24(3):406-15.
View in: PubMed

Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun. 1996-1997; 15(5):213-26.
View in: PubMed

Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment. Oncologist. 1996; 1(1 & 2):88-97.
View in: PubMed

Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol. 1995 Oct 15; 165(2):211-6.
View in: PubMed

CD2 regulates responsiveness of activated T cells to interleukin 12. J Exp Med. 1995 Sep 01; 182(3):721-31.
View in: PubMed

Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A. 1995 Aug 15; 92(17):7779-83.
View in: PubMed

Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma. 1995 Mar; 17(1-2):51-61.
View in: PubMed

Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma. 1995 Mar; 17(1-2):87-93.
View in: PubMed

Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood. 1995 Feb 15; 85(4):1132-7.
View in: PubMed

Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrations. Blood. 1995 Feb 15; 85(4):925-8.
View in: PubMed

Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995 Jan; 13(1):239-50.
View in: PubMed

Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. J Clin Apher. 1995; 10(3):139-43.
View in: PubMed

Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. J Clin Immunol. 1995 Jan; 15(1):51-7.
View in: PubMed

Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science. 1994 Nov 11; 266(5187):1039-42.
View in: PubMed

Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994 Oct 01; 84(7):2109-14.
View in: PubMed

Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. J Clin Invest. 1994 Aug; 94(2):481-8.
View in: PubMed

Alterations in Ca2+ signal transduction in critically ill surgical patients. Surgery. 1994 Aug; 116(2):378-86; discussion 386-7.
View in: PubMed

Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1994 Aug 01; 84(3):964-71.
View in: PubMed

Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells. J Exp Med. 1994 Jul 01; 180(1):241-51.
View in: PubMed

The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation. Transplantation. 1994 May 27; 57(10):1465-73.
View in: PubMed

The effect of minor ABO mismatches on the incidence of graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 1994 Mar 15; 57(5):780.
View in: PubMed

CD antigens 1993. Immunol Today. 1994 Mar; 15(3):98-9.
View in: PubMed

CD antigens 1993. Blood. 1994 Feb 15; 83(4):879-80.
View in: PubMed

Tumor immunity: will new keys unlock the door? J Clin Oncol. 1994 Feb; 12(2):237-8.
View in: PubMed

Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer Suppl. 1994; 8:57-9.
View in: PubMed

CD antigens 1993. J Immunol. 1994 Jan 01; 152(1):1-2.
View in: PubMed

Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents. Bioconjug Chem. 1994 Jan-Feb; 5(1):88-97.
View in: PubMed

Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. Blood. 1994 Jan 01; 83(1):184-90.
View in: PubMed

Prognostic significance of the surface antigens expressed by leukemic cells. Leuk Lymphoma. 1994; 13 Suppl 1:15-22.
View in: PubMed

Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia. Prog Clin Biol Res. 1994; 389:47-63.
View in: PubMed

Fc gamma RIIIA-mediated signaling involves src-family lck in human natural killer cells. J Immunol. 1993 Dec 15; 151(12):6794-800.
View in: PubMed

Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood. 1993 Nov 01; 82(9):2790-6.
View in: PubMed

Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Leuk Lymphoma. 1993 May; 10(1-2):1-8.
View in: PubMed

Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood. 1993 Mar 15; 81(6):1651-7.
View in: PubMed

Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol. 1993 Mar 01; 150(5):1705-14.
View in: PubMed

Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. Bone Marrow Transplant. 1993; 12 Suppl 3:S7-10.
View in: PubMed

Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. Blood. 1992 Sep 15; 80(6):1511-20.
View in: PubMed

Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. J Immunol. 1992 Aug 15; 149(4):1199-203.
View in: PubMed

Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992 Mar 01; 175(3):779-88.
View in: PubMed

Immune-mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. Medicine (Baltimore). 1992 Mar; 71(2):73-83.
View in: PubMed

Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood. 1992 Feb 01; 79(3):576-85.
View in: PubMed

Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease. Blood. 1992 Jan 15; 79(2):481-8.
View in: PubMed

Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992 Jan 15; 79(2):517-26.
View in: PubMed

Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol. 1992 Jan; 22(1):1-6.
View in: PubMed

Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991 Dec; 52(6):1014-9.
View in: PubMed

Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood. 1991 Nov 15; 78(10):2759-67.
View in: PubMed

Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant. 1991 Aug; 8(2):143-5.
View in: PubMed

Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood. 1991 Jun 01; 77(11):2524-9.
View in: PubMed

Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood. 1991 Jun 01; 77(11):2404-12.
View in: PubMed

Monoclonal anti-T cell (T12) antibody treatment of graft-versus-host disease in severe combined immunodeficiency: targeting of antibody and activation of complement on CD8+ cytotoxic T cell surfaces. J Allergy Clin Immunol. 1991 May; 87(5):1029-33.
View in: PubMed

Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991 Mar; 51(3):630-6.
View in: PubMed

Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood. 1991 Feb 15; 77(4):712-20.
View in: PubMed

Biology and clinical relevance of human natural killer cells. Blood. 1990 Dec 15; 76(12):2421-38.
View in: PubMed

Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. Cell Immunol. 1990 Dec; 131(2):352-65.
View in: PubMed

Autoimmune pancytopenia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990 Dec; 6(6):445-7.
View in: PubMed

Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol. 1990 Nov 15; 145(10):3194-201.
View in: PubMed

Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 1990 Nov; 6(5):329-31.
View in: PubMed

Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood. 1990 May 15; 75(10):2076-84.
View in: PubMed

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med. 1990 May 01; 171(5):1509-26.
View in: PubMed

The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1990 Apr; 4(2):369-88.
View in: PubMed

Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A. 1990 Mar; 87(6):2274-8.
View in: PubMed

Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood. 1990 Jan 01; 75(1):296-304.
View in: PubMed

Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. Leuk Res. 1990; 14(5):407-16.
View in: PubMed

Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. Blood. 1989 Nov 01; 74(6):2203-11.
View in: PubMed

Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989 Oct 19; 321(16):1080-5.
View in: PubMed

CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. Nature. 1989 Sep 14; 341(6238):159-62.
View in: PubMed

Clonal evidence for the induction of NKH1 on activated human thymocytes. Functional changes associated with antigen expression. Eur J Immunol. 1989 Sep; 19(9):1735-9.
View in: PubMed

The role of natural killer cells in immune surveillance. N Engl J Med. 1989 Jun 29; 320(26):1748-9.
View in: PubMed

Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells. J Immunol. 1989 Jun 01; 142(11):4105-12.
View in: PubMed

Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplant. 1989 May; 4(3):239-45.
View in: PubMed

Identification of carboxypeptidase and tryptic esterase activities that are complexed to proteoglycans in the secretory granules of human cloned natural killer cells. J Immunol. 1989 Jan 15; 142(2):609-15.
View in: PubMed

Autologous bone marrow transplantation therapy for multiple myeloma. Eur J Haematol Suppl. 1989; 51:157-63.
View in: PubMed

Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood. 1988 Oct; 72(4):1163-7.
View in: PubMed

Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol. 1988 Jul 01; 141(1):131-8.
View in: PubMed

Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci U S A. 1988 Jul; 85(13):4819-23.
View in: PubMed

Induction of natural killer effectors from human thymus with recombinant IL-2. J Immunol. 1988 May 15; 140(10):3660-7.
View in: PubMed

T11/CD2 activation of cloned human natural killer cells results in increased conjugate formation and exocytosis of cytolytic granules. J Immunol. 1988 Feb 01; 140(3):991-1002.
View in: PubMed

Characterization of functional surface structures on human natural killer cells. Adv Immunol. 1988; 42:181-211.
View in: PubMed

Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. Cancer Treat Res. 1988; 38:265-83.
View in: PubMed

Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987 Nov 15; 139(10):3306-13.
View in: PubMed

Lymphoma with clonal T-cell receptor gene rearrangement in a 25-year survivor of Hodgkin's disease. Cancer. 1987 Nov 01; 60(9):2213-8.
View in: PubMed

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987 Jun 11; 316(24):1499-505.
View in: PubMed

Identification and cloning of a prethymic precursor T lymphocyte from a population of common acute lymphoblastic leukemia antigen (CALLA)-positive fetal bone marrow cells. J Exp Med. 1987 Jun 01; 165(6):1749-54.
View in: PubMed

Ultrastructural evidence that the granules of human natural killer cell clones store membrane in a nonbilayer phase. Am J Pathol. 1987 May; 127(2):305-16.
View in: PubMed

Epstein-Barr virus-transformed B-cell line (DV-1) derived from bone marrow of a patient with severe combined immunodeficiency and immunoblastic lymphoma. Pediatr Res. 1987 Apr; 21(4):331-7.
View in: PubMed

Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood. 1987 Feb; 69(2):597-604.
View in: PubMed

Monoclonal antibodies: their use in bone marrow transplantation. Prog Hematol. 1987; 15:137-81.
View in: PubMed

Enhancement of natural killer function through activation of the T11 E rosette receptor. J Clin Invest. 1987 Jan; 79(1):305-8.
View in: PubMed

Activation of natural killer function through the T11/E rosette receptor. Haematol Blood Transfus. 1987; 31:347-50.
View in: PubMed

Monoclonal-antibody-purged autologous bone marrow transplantation for relapsed non-T-cell acute lymphoblastic leukemia in childhood. Haematol Blood Transfus. 1987; 31:67-74.
View in: PubMed

In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. Blood. 1987 Jan; 69(1):246-54.
View in: PubMed

Function of the LFA-1 and T4 molecules in the direct activation of resting human B lymphocytes by T lymphocytes. Eur J Immunol. 1986 Dec; 16(12):1539-43.
View in: PubMed

In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells. J Clin Invest. 1986 Sep; 78(3):666-73.
View in: PubMed

Characterization of antileukemia cells' cytotoxic effector function. Implications for monitoring natural killer responses following allogeneic bone marrow transplantation. Transplantation. 1986 Sep; 42(3):252-6.
View in: PubMed

Use of highly polymorphic DNA probes for genotypic analysis following bone marrow transplantation. Blood. 1986 Aug; 68(2):378-85.
View in: PubMed

A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med. 1986 Jul 01; 164(1):351-6.
View in: PubMed

Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement. A quantitative and functional analysis. Transplantation. 1986 Jul; 42(1):73-80.
View in: PubMed

Expression of the NKTa clonotype in a series of human natural killer clones with identical cytotoxic specificity. J Exp Med. 1986 Apr 01; 163(4):812-25.
View in: PubMed

In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates. J Clin Invest. 1986 Mar; 77(3):977-84.
View in: PubMed

Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood. 1986 Mar; 67(3):722-8.
View in: PubMed

Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates. Cancer Res. 1986 Mar; 46(3):1208-13.
View in: PubMed

Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines. J Immunol. 1986 Jan; 136(1):320-5.
View in: PubMed

Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leuk Res. 1986; 10(1):35-42.
View in: PubMed

Functional surface structures on human natural killer cells. Klin Wochenschr. 1985 Dec 02; 63(23):1189-200.
View in: PubMed

Proteoglycans in cell-mediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis. J Exp Med. 1985 Dec 01; 162(6):1771-87.
View in: PubMed

Specific release of proteoglycans from human natural killer cells during target lysis. Nature. 1985 Nov 21-27; 318(6043):289-91.
View in: PubMed

Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature. 1985 Oct 3-9; 317(6036):428-30.
View in: PubMed

In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. Blood. 1985 Oct; 66(4):961-6.
View in: PubMed

Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985 Sep; 42(2):581-8.
View in: PubMed

Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. J Immunol. 1985 Sep; 135(3):1746-51.
View in: PubMed

Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. J Immunol. 1985 Aug; 135(2):1020-5.
View in: PubMed

The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. J Immunol. 1985 Jul; 135(1):672-8.
View in: PubMed

Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science. 1985 Jun 28; 228(4707):1540-3.
View in: PubMed

Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency. N Engl J Med. 1985 May 02; 312(18):1151-9.
View in: PubMed

Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood. 1985 May; 65(5):1064-70.
View in: PubMed

Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest. 1985 Mar; 75(3):932-43.
View in: PubMed

Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. Cancer Res. 1985 Feb; 45(2):758-67.
View in: PubMed

Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb; 45(2):499-503.
View in: PubMed

Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood. 1984 Sep; 64(3):662-6.
View in: PubMed

Identification of a 140-kDa activation antigen as a target structure for a series of human cloned natural killer cell lines. Eur J Immunol. 1984 Sep; 14(9):844-52.
View in: PubMed

Natural killer-like function of activated T lymphocytes: differential blocking effects of monoclonal antibodies specific for a 90-kDa clonotypic structure. Cell Immunol. 1984 Jul; 86(2):381-92.
View in: PubMed

Clinical applications of monoclonal antibodies in acute leukemia. Ann N Y Acad Sci. 1984; 428:308-17.
View in: PubMed

Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. J Exp Med. 1983 Nov 01; 158(5):1547-60.
View in: PubMed

Use of monoclonal antibodies in autologous and allogeneic bone marrow transplantation. Clin Haematol. 1983 Oct; 12(3):813-32.
View in: PubMed

Identification and molecular cloning of the human Blym transforming gene activated in Burkitt's lymphomas. Nature. 1983 Sep 8-14; 305(5930):112-6.
View in: PubMed

Expression of MY7 antigen on myeloid precursor cells. Int J Cell Cloning. 1983 Apr; 1(1):33-48.
View in: PubMed

Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood. 1983 Apr; 61(4):628-39.
View in: PubMed

Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst. 1983 Mar; 70(3):447-53.
View in: PubMed

Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res. 1983 Mar; 43(3):1389-94.
View in: PubMed

Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature. 1983 Jan 13; 301(5896):158-60.
View in: PubMed

Interferon-induced changes in expression of antigens defined by monoclonal antibodies on malignant and nonmalignant mononuclear hematopoietic cells. J Interferon Res. 1983; 3(2):199-210.
View in: PubMed

In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. Haematol Blood Transfus. 1983; 28:117-23.
View in: PubMed

Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91.
View in: PubMed

Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med. 1983 Jan 01; 157(1):114-29.
View in: PubMed

Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. J Immunol. 1982 Sep; 129(3):1299-305.
View in: PubMed

Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest. 1982 Aug; 70(2):433-42.
View in: PubMed

Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet. 1982 Jul 10; 2(8289):60-3.
View in: PubMed

Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Res. 1982 Feb; 42(2):457-64.
View in: PubMed

Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood. 1982 Jan; 59(1):1-11.
View in: PubMed

Use of monoclonal antibodies as diagnostic and therapeutic reagents in acute lymphoblastic leukemia. Cancer Res. 1981 Nov; 41(11 Pt 2):4771-5.
View in: PubMed

Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. Hum Immunol. 1981 Nov; 3(3):247-59.
View in: PubMed

Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest. 1981 Oct; 68(4):932-41.
View in: PubMed

Expression of a 26,000-dalton glycoprotein on activated human T cells. Cell Immunol. 1981 Oct; 64(1):192-9.
View in: PubMed

Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood. 1981 Sep; 58(3):648-52.
View in: PubMed

Human cell lines express multiple populations of Ia-like molecules. Hum Immunol. 1981 Aug; 3(1):67-76.
View in: PubMed

Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood. 1981 Aug; 58(2):333-6.
View in: PubMed

Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981 Jul; 58(1):141-52.
View in: PubMed

Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood. 1981 Jun; 57(6):1105-10.
View in: PubMed

Surface antigens on malignant Sézary and T-CLL cells correspond to those of mature T cells. Blood. 1981 Mar; 57(3):526-30.
View in: PubMed

Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody. J Immunol. 1981 Feb; 126(2):540-4.
View in: PubMed

Comparative antigenic phenotypes of normal and leukemic hemopoietic precursor cells analysed with a "library" of monoclonal antibodies. Haematol Blood Transfus. 1981; 26:296-304.
View in: PubMed

Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leuk Res. 1981; 5(6):491-5.
View in: PubMed

A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981 Jan; 67(1):134-40.
View in: PubMed

Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol. 1981; 12:187-225.
View in: PubMed

Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. J Immunol. 1980 Oct; 125(4):1506-14.
View in: PubMed

Human leukemia-associated antigen: relation to a family of surface glycoproteins. J Immunol. 1980 Jun; 124(6):2794-9.
View in: PubMed

Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980 Mar; 55(3):395-402.
View in: PubMed

A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature. 1980 Feb 07; 283(5747):583-5.
View in: PubMed

Leukemia-associated antigens in ALL. Blood. 1979 Dec; 54(6):1240-8.
View in: PubMed

Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression. J Exp Med. 1979 Dec 01; 150(6):1472-82.
View in: PubMed

Systemic mastocytosis associated with presence of rheumatoid factor. JAMA. 1976 Apr 12; 235(15):1586-7.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Mayer 530
Boston, MA 02215
Get Directions

Top